Stock comparison
Generate Biomedicines
S&P Global
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GENB
Generate Biomedicines
Market cap
$1.86B
Sector
Financials
SPGI
S&P Global
Market cap
$123.61B
Sector
Financials
Overall winner
S&P Global SPGI
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GENB | SPGI | Winner |
|---|---|---|---|
| Warren Buffett | 52D | 74C | SPGI |
| Benjamin Graham | 44D | 66B | SPGI |
| Philip Fisher | 78B | 70C | GENB |
| Peter Lynch | 100A | 68C | GENB |
| Joel Greenblatt | 4F | 42D | SPGI |
| Charlie Munger | 77D | 70B | GENB |
| Terry Smith | 79B | 70B | GENB |
Side-by-side metrics
| Metric | GENB | SPGI |
|---|---|---|
| Market cap | $1.86B | $123.61B |
| P/E (TTM) | - | 25.1x |
| EV/EBIT | - | 20.3x |
| ROIC (TTM) | -89.38% | 9.89% |
| Gross margin | 100.0% | 70.47% |
| Net margin | -6.37% | 30.37% |
| Revenue CAGR 5y | 55.89% | 16.6% |
| EPS CAGR 5y | - | 3.96% |
| Debt / Equity | - | 0.4x |
| Dividend yield | 0.0% | 0.95% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GENB leads on
- EV/EBIT-vs 20.3x+142%
- Debt / Equity-vs 0.4x+125%
- P/E (TTM)-vs 25.1x+116%
- Revenue CAGR 5y55.89%vs 16.6%+70%
SPGI leads on
- ROIC (TTM)9.89%vs -89.38%+111%
- Net margin30.37%vs -6.37%+105%
- Dividend yield0.95%vs 0.0%+100%
- Market cap$123.61Bvs $1.86B+98%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.